Sunday, May 19, 2019 9:57:08 PM
I admire your persistence re the ERP/EEG “scent” in tracking its benefit in making our trials, as well as others’ hereout, shorter, more cost effective, higher efficiency and greater accuracy compared to trials of old. Work smart, not hard, and with better results.
I made an extra effort to dig into the Cognision site, approval trials, design and function. I studied why my machine learning investment program likes the “slow, steady” enrollment of our AD trial and assigned it a higher probability of success. I reread your thesis, several times.
Try this on, buddy:
ERP/EEG data can, in fact, shorten our trial for AD with greater precision! Here’s the high level summary of how:
Assume we have fewer sites in Australia conduct the trial. I’m assuming 11 would be ideal. My thought process is that Dr M and team, having found success in the ph2a, success defined as the vast majority of patients having slower decline than historical models (and slightly over 20% having reversal of symptoms 7/32), will now reconstruct 11 similar trials with the same “n”. This time, the trials will include a placebo set within each group to take the place of historical data - but should return the same results (*/-).
It then follows that if the dosed patients (2/3 at each site) are able to be very accurately measured as to mental decline or increase or stability in cognitive brain signals across a battery of tests, by the ERP - that’s what it detects very accurately and gained approval for, it can be demonstrated that the results of 2/3 of the patients, n less (non placebo), outperform the placebo group (1/3) or do not. No human bias. Measured brain signals. This rules out RWE and stands on hardcore science alone. After the fact or in addition, RWE can be included as well, of course. And, doses should correlate as well. ERP will be our truest ally in validating these results.
“An ERP system records electrical signals at the scalp that are produced by the brain when performing cognitive tasks. By doing this study, we hope to evaluate various performance parameters of the COGNISION(TM) system.”
This is from the 2010 FDA clinical trial which approved Neuronetrix’s ERP.
Now, why “less is more”:
If we use 70 sites, we may enroll patients faster, however, the ERP data will be for each site which will contain approximately 6 patients. 2 of these will be placebo. 2 will be low dose. 2 will be high dose. 80% will carry the wild type gene. 20% will carry the less responsive gene. Once this is all mixed into one single outcome, there will be a bunch of small “n”’s which may not show the overall picture especially during a rolling enrollment.
If we go with higher “n”’s and fewer sites, the 1/3, 2/3 and gene breakouts will be able to be compared across 11 sites to demonstrate via ERP that there is efficacy above placebo.
If that’s the case and the approved machine is able to show consistency across the board at several 35 n sites, we have a strong enough case to be made at 6 mos. My opinion. Along with safety, RWE, the extension data and any other indications which may have received approval at that point.
I think this is how the ERP should be our battle ax - reproducing similar results across blocks of decent sized n’s against placebo with discernible outcomes, not as an overall mix.
This is like running 11 small trials and getting a “pass” and same grade range on each. Not one pass/fail exam.
Also, when patients complete the trial (if so) and are switched from placebo to active drug since justification for equipoise would be inhumane at that point, we present stronger evidence if there is efficacy signal.
As you said in one of your previous posts, We have the proof and we will show them.
This is how I would proceed to make the case in a short, accurate trial using ERP/EEG REAL TIME. 11 stat sig models in same range measured without bias and calibrated across sites, will blow a single result of 450 pts out of the water, IMO.
That’s why my program liked it...Xena was right - it IS biased! But, there’s wisdom in designing it in this fashion. Why “cut for high card” for all the stakes, when we can demonstrate that we can beat the house, 11 “hands” in a row?
Open for thoughts and rebuttals.
And, even though the outcome may be the same (should be) as with the whole trial overall, this allows us to show that no matter how you slice it (by CRO, by subjective personnel, by rolling enrollment - time of year - it’s winter down there now! by geographical location) you will always end up with the same data. Missling said we would be allowed to check on interim data, I believe. This would put that to good use.
Signing off to give you time to digest and think - but still in earshot.
I have to admire your persistence. I salute you! (It motivated me to hatch this).
Great posting, Nidan! I respect those who do not go quietly away without answers! :) thumbs up
Biostock
Recent AVXL News
- Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia • GlobeNewswire Inc. • 10/17/2024 11:30:00 AM
- ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • InvestorsHub NewsWire • 10/15/2024 12:21:48 PM
- ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • InvestorsHub NewsWire • 10/01/2024 11:00:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM